{"ticker": {"uuid": "f715f74c-b258-4cc2-9c0f-00617f889540", "symbol": "BIIB", "name": "Biogen Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Biogen Inc. stock outperforms competitors despite losses on the day", "summary": "Biogen Inc. (BIIB) shares declined by 1.05% to $196.58, despite an overall positive trading day for the broader market, with the S&P 500 and Dow Jones Industrial Average both rising. The stock closed 4.56% below its 52-week high achieved on May 13th.", "url": "https://www.marketwatch.com/data-news/biogen-inc-stock-outperforms-competitors-despite-losses-on-the-day-084aaaa5-cbce73798763?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-18T16:59:00", "published_display": "18 Jun 2026 16:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen adds more immune drugs in $1B buyout of secretive startup Raythera", "summary": "Biogen has moved to acquire the secretive startup RayThera for up to $1 billion, aiming to boost its immunology drug pipeline. RayThera, founded in 2023, has kept its specific drug targets largely under wraps, but patent filings suggest it's working on modulators for TNF activity", "url": "https://www.biopharmadive.com/news/biogen-raythera-deal-acquire-immune-drugs/823241/", "source_name": "BioPharma Dive", "published_at": "2026-06-18T16:07:09", "published_display": "18 Jun 2026 16:07", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline", "summary": "Biogen (NASDAQ: BIIB) announced its agreement to acquire private biotechnology company RayThera Inc. for up to $1 billion, intending to expand its immunology pipeline. The deal involves an upfront payment and consideration tied to future clinical and regulatory milestones, with a", "url": "https://www.benzinga.com/m-a/26/06/53280277/biogen-to-acquire-raythera-for-up-to-1-billion-expanding-immunology-pipeline", "source_name": "Benzinga", "published_at": "2026-06-18T15:07:12", "published_display": "18 Jun 2026 15:07", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen snags San Diego biotech for $1B as immunology expansion continues", "summary": "Biogen is acquiring San Diego-based biotech RayThera for up to $1 billion to expand its early-stage immunology pipeline. The Cambridge drugmaker's deal focuses on developing therapies for immune-mediated conditions. This acquisition marks a significant move for Biogen in strength", "url": "https://www.bizjournals.com/boston/news/2026/06/18/biogen-raythera-acquisition.html", "source_name": "The Business Journals", "published_at": "2026-06-18T14:21:13", "published_display": "18 Jun 2026 14:21", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Biogen Inc. (NASDAQ: BIIB) on behalf of its investors. The investigation stems from Biogen's May 14, 2026 announcement of \"topline results\" from its Phase 2 CELIA study for an Alzheimer's drug, diranersen, w", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-biogen-inc---biib-302802811.html", "source_name": "PR Newswire", "published_at": "2026-06-18T14:07:12", "published_display": "18 Jun 2026 14:07", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Enters $1 Billion Agreement to Acquire RayThera Inc.", "summary": "Biogen has agreed to acquire private immunology biotech RayThera Inc. for up to $1 billion, significantly expanding its pipeline with a new class of undisclosed small molecule anti-inflammatory candidates. This strategic move aims to deepen Biogen's involvement in immunology, com", "url": "https://www.pharmexec.com/view/biogen-enters-billion-agreement-acquire-raythera-inc", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-18T13:44:16", "published_display": "18 Jun 2026 13:44", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen acquires RayThera in deal worth up to $1 billion", "summary": "Biogen has announced the acquisition of RayThera in a deal potentially valued at up to $1 billion. This strategic move aims to expand Biogen's portfolio and capabilities. The specific therapeutic areas or technologies RayThera brings to Biogen were not detailed in the provided co", "url": "https://qz.com/biogen-raythera-acquisition-immunology-061826", "source_name": "Quartz", "published_at": "2026-06-18T13:44:16", "published_display": "18 Jun 2026 13:44", "sentiment": "positive", "sentiment_pct": 68, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout", "summary": "Biogen (BIIB) is set to acquire RayThera Inc. for up to $1 billion, a move designed to bolster its immunology pipeline with anti-inflammatory candidates currently in early-stage development. This acquisition is part of a broader trend of increased merger and acquisition activity ", "url": "https://finance.yahoo.com/healthcare/articles/biogen-strengthen-immunology-pipeline-1b-135100719.html", "source_name": "Market source", "published_at": "2026-06-18T13:37:12", "published_display": "18 Jun 2026 13:37", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham reiterates Buy on Biogen stock after RayThera acquisition By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQd1AxRi1PUEVuclV5VzNQU1VlQjA0cUh6bkQ5SjFIb3QtU184M3hwZndfZFFnelVyd01CTXhxU0hReHN0cTVuZHprMXFRNUNEenFjOERmbTBVVHh1dmw1R0w4RlFMYWlFMTZqanZZQ1VfdV9nUXJrS0k3NWRXSWVYYVRHai1udDNqUldiXzFfUWVvWmV4ekIwV2VpTUhkUklTVTRzcUJERFZyWXhGSkdROE9vNlVNdEdNa2ZSbWwzVTVSaUlm?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-06-18T12:23:16+00:00", "published_display": "18 Jun 2026 12:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Agrees to Acquire RayThera for Up to $1B", "summary": "Biogen Inc. has announced its agreement to acquire RayThera Inc., a private biotechnology company specializing in small molecule therapies for immunology, for up to $1 billion. The acquisition includes an upfront payment and additional payments contingent on achieving future clin", "url": "https://www.contractpharma.com/breaking-news/biogen-agrees-to-acquire-raythera-for-up-to-1b/", "source_name": "Contract Pharma", "published_at": "2026-06-18T12:54:24", "published_display": "18 Jun 2026 12:54", "sentiment": "positive", "sentiment_pct": 81, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham reiterates Buy on Biogen stock after RayThera acquisition", "summary": "Needham has reiterated a Buy rating and a $255.00 price target on Biogen Inc. following its acquisition of RayThera. The acquisition, valued up to $1 billion, brings in multiple anti-inflammatory assets to bolster Biogen's immunology pipeline, with the lead candidate expected to ", "url": "https://www.investing.com/news/analyst-ratings/needham-reiterates-buy-on-biogen-stock-after-raythera-acquisition-93CH-4749704", "source_name": "Investing.com", "published_at": "2026-06-18T12:08:10", "published_display": "18 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Raises Price Target on Biogen to $224 From $206, Keeps Equalweight Rating", "summary": "Morgan Stanley has increased its price target for Biogen (BIIB) to $224 from $206, while maintaining an \"Equalweight\" rating on the stock. This update comes as Biogen recently announced its intention to acquire RayThera in a deal valued up to $1 billion to enhance its immunology ", "url": "https://www.marketscreener.com/news/morgan-stanley-raises-price-target-on-biogen-to-224-from-206-keeps-equalweight-rating-ce7f5cdddc8df026", "source_name": "marketscreener.com", "published_at": "2026-06-18T10:37:07", "published_display": "18 Jun 2026 10:37", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPX09wV1FjeVZ1YlVJLTl0M3VzMWo1OWdpM0RnamVaaUlrTjBpR1VJVlAwZnNyOTdzaWZFX2RaNmZ4R19FcTk0bi1HSlZROFpVU1Mxc3Fia1VkRi1nS0NmZUQ2dXowZkNMVWJkMmlxYm1iOTQ0bWJlYV9qQmRnQlFQenBobjlEN2RveDV1MER3V1pYTWxqVW5Hc3FQQmk1a19sSjVXTnF5bHdlUQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T08:37:36+00:00", "published_display": "18 Jun 2026 08:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) to Acquire RayThera for Up to $1 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOYUUtb20yMlZDMWgzV1NVWUg1Qmdfc0ZRSWdqczQ3eXR2X3dQbWd1Q1pqYjJKUlM1NVh0a0tJdTJQVXYzSGREYklhcGFmaGI0Y25PV0dqU3AtX2hRc3VOdkY4b28zRVlfRHZVOFZINDIzYjNESV9tTXR5SUFNcmdNU1RUSXhXbXh4YWF5QUZkSUdaY2RZcko5UEtRcjlIMEpQV3Zlbg?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T06:03:14+00:00", "published_display": "18 Jun 2026 06:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Biogen Inc. (BIIB) investors after the company announced that its Phase 2 CELIA study for diranersen failed to meet primary endpoints, causing a 6.4% stock price drop. The firm encourages investors ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/biogen-inc.-biib-investigation-bronstein-gewirtz-and-grossman-ll-1173756", "source_name": "ACCESS Newswire", "published_at": "2026-06-18T01:37:07", "published_display": "18 Jun 2026 01:37", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPb3JfYlhZeDZpZTE5X3REb2NYcUtUVTZaaFBzZ2dWaW1pcER4M2YxNjRlUkRjVklvVkRxRVc2VXYyUWVROGVQTy1FNExZVk45clpFbllwQWNXeGRwbUQ3d1VRSVJLd0FzWmZKcjlvOVg5ejdnUnJMSGhidUVNUGNhRUJhQlRJWFJXblJUYXRkNWtEWEZzNG1CYjdCdmJodGt0M2Z6cTZoWUZXdXRaNnNEd1AzWS1YTU96bHlCa0tFdmpfMmQ0a0lQMW9VM3pTRTYyN2hDX25nVDFoa0J4WDlZ?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-18T00:06:43+00:00", "published_display": "18 Jun 2026 00:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen to Acquire RayThera for Up to $1 Billion to Expand Immunology Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQMEk4Y0Q2RHY1SlJjUTgyVUJRSDh1elRnRTV0ZEZwMjJ2UnpIdUg2RzRxYWhfaXJRa2JrLU9UQTR0dXA2dXlwVDRqMTlJdUZ3Wk4yLTlTSnJHYjk4RU9Sb2Vqc3FabnNQZUltNTdrM0ZaNnBQeDZ0WUhOSU9BUFpnSV9wS1VzTUU1Ty1XQmdCWnVvRzk2Qk5wV2FjTzk0TkZ2Y0hFdFV6bkZDTW9mSTZxX3BR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T23:10:00+00:00", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen pays up to $1B to add RayThera immunology assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNRGpGQU1JeXppRTBmR0FqTkZhMG9kWW9ROVYxMGVWQkFmcmlXQkU5ZE1xZUlCVE9IM0pNZEhnbkREb0JMYnZxSXA2UkZSN0lFOGFoSjlrMThSNlNpcXI4UEZjS09aWXpDXzc0MEE2OWZEQXlLbl9YbUlNM0p6aWFEZDhxX1N0TUo2ME5uOEM2LWh3UEVKQmt1MHo0RFM3eXhlUjd1NExtUFJKMlhoM3AyTzU1el9PbUU1M2pB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T22:59:00+00:00", "published_display": "17 Jun 2026 22:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. stock underperforms Tuesday when compared to competitors", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNMHZfZ0ZGY2x6eUhGbE1qNVJMb0REdVFCVnZGQnFKYy1HSzJiTE1IS2dTM3FUTW5IRFhqUHpENFlJTDlaMVFDSkR5MHlMX18zWFlXOWQyWlV0d3ljTjBrV1c5dXB2TTNZa3lDazlLUXh5S09RTkhSdjBvdy1aZFBjY1dESVROS2tGZ2tVUzN0Y0taZERKbGhNUWZ2UzBVa1lIcWlsU3I1b0NaTTd0ZEdMTFdDNWVZM09CTjEwdW53SHVfS2l1VlE?oc=5", "source_name": "MarketWatch", "published_at": "2026-06-16T20:58:00+00:00", "published_display": "16 Jun 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) Stock After Breakthrough SMA And Lupus Updates Is A 9.4% Undervaluation Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T03:45:20+00:00", "published_display": "16 Jun 2026 03:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. Stock (US09062X1037): Analyst Needham Sticks With Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNSmd4dktvY3h3LXlmZjBmd3J2b3dmaGtURDYxdnNnYWJ6X2ZsUlBwSmp0RHdGTG96V0RQcHgxOWRGc2d5WE5wbUswdlhNUE9EYWdmS1AzOE02aTduQmxwd1pHQ2c4c1AwOTVMRFY5RWsyNW5UVE5odEd4RGRUb0hBZm5DSXBoYTNPdmNkb3Y4RG1QMnR3eFpiQVZkYlpoZGItc2NIeTV1UWJyUDJTTVBjRlVrQ2lqSWFxOXVoM3hFdGRibHU4MGc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-14T20:51:18+00:00", "published_display": "14 Jun 2026 20:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. stock (US09062X1037): Alzheimer\u2019s setback, pipeline hopes and what\u2019s next", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZ0hxUm5GNjk2M3hHeFYtMmVLMG10b0hJTVIxWUMtbVk3T3VEaTVGX2dqNUJ3aEZwRzAzbmR1SVA5WXhWV29XX1VwSkc5THBla2wzNDgwSXJPNEJBRURYdmpybl9CS2VUY2VfMmsxRlFyVkxuOG9EZktiejBwMlVHYmk2S1Rta2lZRnFzVkRNQktjeEw3R3R5NXBuSGhGajVnM0FWalFsVGdKUi0tbGczSDQzRGZnblBuckhaek96MEI?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-10T19:29:45+00:00", "published_display": "10 Jun 2026 19:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Stock (BIIB) Opinions on Congressional Purchases and Analyst Upgrade", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOU0NTdmVsYmd3VGZWbVR0ZGxKWkoxQlBjU1ozY0JWYWdMSHdISW4zMTNwa0h5NFNMT2FEQVprc3Q5Y1BsbTR5bU5ZT3YwNjdXYngtejZNMXFjX1IyX2plYmVvX1dzalM4Z2txUzVJT1BGUWw4eFhOemt1R182VTgwTF9Jb3I3bDdmTjV5QnJJUGlOUU5tLTRwdFR5bWZMU0xCR0ZwZEJBNlkzWi1kYVBjcmhOVkFEQQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-10T04:13:12+00:00", "published_display": "10 Jun 2026 04:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. stock (US09062X1037): Alzheimer\u2019s portfolio and pipeline in focus after recent updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQbU4za0RNZXZQSVRNODhIdG5sNlNHc2ZnTDFFcl9ZLXdUdjlnYXMtNWVXUWNUb2Y2U3RTUktpaWRsTF9jZHhBV1V6T3h5ZVlJN3dVS3h2N2t6MXpmdEV2Xy1hVm1iczh5RlJzYklycWRvV2ozSDJTajVBZUJOU2RndHBtTV9adGt6X3k2b21kLUVmdnBWUWxrNnFRZ1pNamw3WUx5WkJRZ3Zhb0Nrb3hya1NfMWMyS3Zldm56OGN6N3hoVzF2?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-08T14:54:51+00:00", "published_display": "08 Jun 2026 14:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Biogen (BIIB) Valuation After Breakthrough Therapy Status And Positive Lupus Trial Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T10:24:54+00:00", "published_display": "08 Jun 2026 10:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital raises Biogen stock price target on pipeline potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQbTZYT2ItMUZxNW53RHNjbUdYY09GWEVsR2UwRTJiU3hJaDV1RnJWUi1mVjkxcUhIajVGQjZ2bnJCV2RUVG9ySW12LS1FV0xRUFI5ZjhBNXFWYzJhcFRvUVpXYjFXaUhvd2hMWWdaQ2xXRFU4c190Yl95VWIwUnRpQTFsWlBha090cDJLWmJ2ZzdYRkw3T1FueHIxdjQwVDF0YVZXd1FrX01Fb01nbC1xejZWN2hJTGliMjgwemp1OUhQR0xk?oc=5", "source_name": "Investing.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. stock (US09062X1037): Alzheimer\u2019s franchise and pipeline in focus after recent develop", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOaGU1R24xcW50aDVRa2RURklmTTNCYWNrX0ZLUnd5WHRPSmxXeldKaWM2RHQweFpKaFhWbVdpSF85WllHQkthX3p1eVRvUGpRSGhxVjJreDhuRE9ySi0zUF84YXAzd3BJeGNiMlRJZFV3R1ZacjJWSUphamNfZTkwVVNxQ0tXcnpqS1dsaFQyOVNHWjRoM1ZuVDN0ZXVaM2VDeFFKTVB1YWhLX0dXRS0tWlJnaFJmMDQ1dml4SGctRG9mTG1Y?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Wall Street Analysts Bullish on Biogen Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOU1IxbUZOOHBjX1ZEUFFQMmY2Rng0Y3RjX2FOMEFVS2RoRTBzN19Ld1FnWDJORlhfVUNHWEVZTFRsdDY1SW00QUdfU1hyQXpSX3ZWVkJmRlJYT0U5RzBIcGs4YktKWFY5eWstbnBJcFpfZ3VBMUVLWjZ4aU5lOWVHRVBXdkJYc0FOejlsSndOTTRqUS01a0g0aS1ILW84Um8wRGc?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has The Market Overlooked Biogen (BIIB) After A 62% One Year Share Price Jump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) One Off US$1.1b Loss Tests Bullish Earnings Growth Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQR2RjaUo0NFhER0dGMGZseEd3QzhvVGFpb01NcTk2c1VpcXdQMjhJM1ZUdzVCZ0g0UnFWVDZLOEpjQkNCTkhwaTVROXdXWWMya1h0Uno2ZU9Iei1RSzllOTNlaW5GUDVqU3QxRndaN3UxanA4cllFT0g3ZnB3V29DaWdxT21vUDRSUHFiX3VXelZpUy0zMFNpeXJfVVJCVENPVzVGY2NBdTBOSFFRSFlFWDlHUTBXLWJQSE1tZnhn?oc=5", "source_name": "TradingView", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) Stock Trades Up, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNek03UkJPMmJFMlJJV1VxeGMwcjRFamV2T251SEdnVGhUbXlCWldWSnBYUU0tNDdGdkxPVVhsX0RYdkpNUnZYcEtJLVk1U244aE5JMHVTMGJ0TURINWtxcEotYUkteXc4RjVoRnZwNmNRYVBodjFZZ3ZxS0hybE1XMHhMaUhyekR0RlY4SzdQQnJ1ODJUY21xVQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Biogen (BIIB) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNbGpLVEh5ck9BQzY5d1haWWlzbGRaOXliOFVxajJJY0xSVnAzQ0NjNU5WTFJmdlJUbGVYOGRSTFVyaGVfbV9WZ1N4d01ndEFwYXpBNnlHaXFuUUgyM0pta1RhRWRXeEJ0Z0NlU3pYMkVPMDEyNHA2bUxuaWFPUHJFV3dwbURUckRYQ0EwUGpBbjljdlJkcjY0RVR5cFE?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxORmRxVFJrUXVPOUF3dGZiR2IwTmJ4RDVhSUlyWWFtNC0xSWs1Rm9ocWQ0MVlCenhtMGsyMVVHOV9aNkNFMDlaMndQNXVUd05QRUJfbW9fRS1xMmtZcUNxVGJoMXZrY3VWYVFDQmI2T3NEdDExZDFIWU50Q256Rk15STlxbDVVYXBfTG1Ea2tPT0YwWnZlZTlac04wbjZGbGdEamwybnc0QTA0dTNodlpmOXpPRXRlc25aM1kzMlljZDRnZUZPczBSekVIQ2FMWlNJY0Q2anVBYk5PMzEweV9nSjBQQjR3VUNmR0dWWDVXOTItczdnUXpWaDJQajB1di11a21RMg?oc=5", "source_name": "StockStory", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: Apellis shares double on Biogen's $5.6 billion buyout plan", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNNGxkcnZoWTJSX0xRNVhTZVg3ZXF0aks5S1UtOUdPNmxQUUNod1FtcXdJMkNlZmwzSkFXbG03WURWaXVpWlhWYlowMXIyLUlhaFJxdjVvSWZoU1ZqbkZmelctTWhXVDBYZXU2U3owVUlCTThXOUhwLVYwYTRxMFVHYmFpU2tXbXRSMTRVY2RybEYyemFsek0zZWxNakpfZDI2Z0ZBVVF6VTNCWDBYRHJNMmJpamFDLTA4T25TV0xLVldkMzJBTmVqc0FHNFFSeGpIWjdmNnF0WWc1cjRrQ3haU0U5elFWSUNMVnRmZ1lfa3BjbXVQZl9QUlZ30gH_AUFVX3lxTE9xZkx4bVRGdWE5NF96b0dNTGx4bnBNSlhKWUtlVXVMSmFndDlOLV9Yd29wSXVwWllJUmxJMlo4UnM5VVp2S3FqZElkZGNWMmw0a290V05vRlVtNVUzR1lZRHU4Vm51Z2o5dElvdTlIZEJ3cHgzMHU4d1hBVFNsMVlwT3N5NFY0ZFEtZHhDZW9MQ1RMT2M0YnVlN2pIdEtubVRweUJuMktWVGFxU3F0S1NyUVFZbDdVWVZuVktZSHdvWkpNQUhaNk1NLVF4bHFIV2ZtTGNoQ1RTUl9DRm9TczhSUlIwRmZoVWdwZDlTYVVCQ3Vqbm9DVWFiQXhkeENvNA?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPbzVIbFFpSTl1Q19PNjVMZnZJWW8wTVhpcnBiN3lmWUFFVlB5X3B6SzYxYnR3R0VLWEYxRllZbXVySTdIZFgwYkswUlRWZ0piX2hYT05McjRjaEJBZERqUHM0ZDBpTEx3VDRNQVBEVjNJNG5EakxJQ3N2Mm5KZlJjdkp5akVQLTZCVTluVUFNWDdwMVBFRWU3RkJWU3F4aEpaUkFZYjRXZk03TlRqRGI2U3JWWXU3c3M?oc=5", "source_name": "TradingView", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQUE9KY3dYNktNZWVBbGM2M3F4VmUxSkxGX2RKSVM1ZUtRNjQ0UG8tUDdPSXpESVQyRU5BOW4wRXE2YmtSaTQzam9zLWI2ZUJRN3l2S1Jrd1p5dW5PaHc3NXdmb1hsQ1BBbUpqRnZmYkh1Q05KOUtrc05tMFhyRXVVTWotcnVIbVhiTGMyV2RUbjlyNU0yazBiOTZB?oc=5", "source_name": "CNBC", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has C4 Therapeutics\u2019 (CCCC) Biogen Partnership Become a Defining Test of Its Collaborative Model?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-17T07:00:00+00:00", "published_display": "17 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Biogen Inc. stock outperforms competitors despite losses on the day", "summary": "Biogen Inc. (BIIB) shares declined by 1.05% to $196.58, despite an overall positive trading day for the broader market, with the S&P 500 and Dow Jones Industrial Average both rising. The stock closed 4.56% below its 52-week high achieved on May 13th.", "url": "https://www.marketwatch.com/data-news/biogen-inc-stock-outperforms-competitors-despite-losses-on-the-day-084aaaa5-cbce73798763?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-18T16:59:00", "published_display": "18 Jun 2026 16:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen adds more immune drugs in $1B buyout of secretive startup Raythera", "summary": "Biogen has moved to acquire the secretive startup RayThera for up to $1 billion, aiming to boost its immunology drug pipeline. RayThera, founded in 2023, has kept its specific drug targets largely under wraps, but patent filings suggest it's working on modulators for TNF activity", "url": "https://www.biopharmadive.com/news/biogen-raythera-deal-acquire-immune-drugs/823241/", "source_name": "BioPharma Dive", "published_at": "2026-06-18T16:07:09", "published_display": "18 Jun 2026 16:07", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline", "summary": "Biogen (NASDAQ: BIIB) announced its agreement to acquire private biotechnology company RayThera Inc. for up to $1 billion, intending to expand its immunology pipeline. The deal involves an upfront payment and consideration tied to future clinical and regulatory milestones, with a", "url": "https://www.benzinga.com/m-a/26/06/53280277/biogen-to-acquire-raythera-for-up-to-1-billion-expanding-immunology-pipeline", "source_name": "Benzinga", "published_at": "2026-06-18T15:07:12", "published_display": "18 Jun 2026 15:07", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen snags San Diego biotech for $1B as immunology expansion continues", "summary": "Biogen is acquiring San Diego-based biotech RayThera for up to $1 billion to expand its early-stage immunology pipeline. The Cambridge drugmaker's deal focuses on developing therapies for immune-mediated conditions. This acquisition marks a significant move for Biogen in strength", "url": "https://www.bizjournals.com/boston/news/2026/06/18/biogen-raythera-acquisition.html", "source_name": "The Business Journals", "published_at": "2026-06-18T14:21:13", "published_display": "18 Jun 2026 14:21", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Biogen Inc. (NASDAQ: BIIB) on behalf of its investors. The investigation stems from Biogen's May 14, 2026 announcement of \"topline results\" from its Phase 2 CELIA study for an Alzheimer's drug, diranersen, w", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-biogen-inc---biib-302802811.html", "source_name": "PR Newswire", "published_at": "2026-06-18T14:07:12", "published_display": "18 Jun 2026 14:07", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Enters $1 Billion Agreement to Acquire RayThera Inc.", "summary": "Biogen has agreed to acquire private immunology biotech RayThera Inc. for up to $1 billion, significantly expanding its pipeline with a new class of undisclosed small molecule anti-inflammatory candidates. This strategic move aims to deepen Biogen's involvement in immunology, com", "url": "https://www.pharmexec.com/view/biogen-enters-billion-agreement-acquire-raythera-inc", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-18T13:44:16", "published_display": "18 Jun 2026 13:44", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen acquires RayThera in deal worth up to $1 billion", "summary": "Biogen has announced the acquisition of RayThera in a deal potentially valued at up to $1 billion. This strategic move aims to expand Biogen's portfolio and capabilities. The specific therapeutic areas or technologies RayThera brings to Biogen were not detailed in the provided co", "url": "https://qz.com/biogen-raythera-acquisition-immunology-061826", "source_name": "Quartz", "published_at": "2026-06-18T13:44:16", "published_display": "18 Jun 2026 13:44", "sentiment": "positive", "sentiment_pct": 68, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout", "summary": "Biogen (BIIB) is set to acquire RayThera Inc. for up to $1 billion, a move designed to bolster its immunology pipeline with anti-inflammatory candidates currently in early-stage development. This acquisition is part of a broader trend of increased merger and acquisition activity ", "url": "https://finance.yahoo.com/healthcare/articles/biogen-strengthen-immunology-pipeline-1b-135100719.html", "source_name": "Market source", "published_at": "2026-06-18T13:37:12", "published_display": "18 Jun 2026 13:37", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham reiterates Buy on Biogen stock after RayThera acquisition By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQd1AxRi1PUEVuclV5VzNQU1VlQjA0cUh6bkQ5SjFIb3QtU184M3hwZndfZFFnelVyd01CTXhxU0hReHN0cTVuZHprMXFRNUNEenFjOERmbTBVVHh1dmw1R0w4RlFMYWlFMTZqanZZQ1VfdV9nUXJrS0k3NWRXSWVYYVRHai1udDNqUldiXzFfUWVvWmV4ekIwV2VpTUhkUklTVTRzcUJERFZyWXhGSkdROE9vNlVNdEdNa2ZSbWwzVTVSaUlm?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-06-18T12:23:16+00:00", "published_display": "18 Jun 2026 12:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Agrees to Acquire RayThera for Up to $1B", "summary": "Biogen Inc. has announced its agreement to acquire RayThera Inc., a private biotechnology company specializing in small molecule therapies for immunology, for up to $1 billion. The acquisition includes an upfront payment and additional payments contingent on achieving future clin", "url": "https://www.contractpharma.com/breaking-news/biogen-agrees-to-acquire-raythera-for-up-to-1b/", "source_name": "Contract Pharma", "published_at": "2026-06-18T12:54:24", "published_display": "18 Jun 2026 12:54", "sentiment": "positive", "sentiment_pct": 81, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham reiterates Buy on Biogen stock after RayThera acquisition", "summary": "Needham has reiterated a Buy rating and a $255.00 price target on Biogen Inc. following its acquisition of RayThera. The acquisition, valued up to $1 billion, brings in multiple anti-inflammatory assets to bolster Biogen's immunology pipeline, with the lead candidate expected to ", "url": "https://www.investing.com/news/analyst-ratings/needham-reiterates-buy-on-biogen-stock-after-raythera-acquisition-93CH-4749704", "source_name": "Investing.com", "published_at": "2026-06-18T12:08:10", "published_display": "18 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Raises Price Target on Biogen to $224 From $206, Keeps Equalweight Rating", "summary": "Morgan Stanley has increased its price target for Biogen (BIIB) to $224 from $206, while maintaining an \"Equalweight\" rating on the stock. This update comes as Biogen recently announced its intention to acquire RayThera in a deal valued up to $1 billion to enhance its immunology ", "url": "https://www.marketscreener.com/news/morgan-stanley-raises-price-target-on-biogen-to-224-from-206-keeps-equalweight-rating-ce7f5cdddc8df026", "source_name": "marketscreener.com", "published_at": "2026-06-18T10:37:07", "published_display": "18 Jun 2026 10:37", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPX09wV1FjeVZ1YlVJLTl0M3VzMWo1OWdpM0RnamVaaUlrTjBpR1VJVlAwZnNyOTdzaWZFX2RaNmZ4R19FcTk0bi1HSlZROFpVU1Mxc3Fia1VkRi1nS0NmZUQ2dXowZkNMVWJkMmlxYm1iOTQ0bWJlYV9qQmRnQlFQenBobjlEN2RveDV1MER3V1pYTWxqVW5Hc3FQQmk1a19sSjVXTnF5bHdlUQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T08:37:36+00:00", "published_display": "18 Jun 2026 08:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) to Acquire RayThera for Up to $1 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOYUUtb20yMlZDMWgzV1NVWUg1Qmdfc0ZRSWdqczQ3eXR2X3dQbWd1Q1pqYjJKUlM1NVh0a0tJdTJQVXYzSGREYklhcGFmaGI0Y25PV0dqU3AtX2hRc3VOdkY4b28zRVlfRHZVOFZINDIzYjNESV9tTXR5SUFNcmdNU1RUSXhXbXh4YWF5QUZkSUdaY2RZcko5UEtRcjlIMEpQV3Zlbg?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T06:03:14+00:00", "published_display": "18 Jun 2026 06:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Biogen Inc. (BIIB) investors after the company announced that its Phase 2 CELIA study for diranersen failed to meet primary endpoints, causing a 6.4% stock price drop. The firm encourages investors ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/biogen-inc.-biib-investigation-bronstein-gewirtz-and-grossman-ll-1173756", "source_name": "ACCESS Newswire", "published_at": "2026-06-18T01:37:07", "published_display": "18 Jun 2026 01:37", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPb3JfYlhZeDZpZTE5X3REb2NYcUtUVTZaaFBzZ2dWaW1pcER4M2YxNjRlUkRjVklvVkRxRVc2VXYyUWVROGVQTy1FNExZVk45clpFbllwQWNXeGRwbUQ3d1VRSVJLd0FzWmZKcjlvOVg5ejdnUnJMSGhidUVNUGNhRUJhQlRJWFJXblJUYXRkNWtEWEZzNG1CYjdCdmJodGt0M2Z6cTZoWUZXdXRaNnNEd1AzWS1YTU96bHlCa0tFdmpfMmQ0a0lQMW9VM3pTRTYyN2hDX25nVDFoa0J4WDlZ?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-18T00:06:43+00:00", "published_display": "18 Jun 2026 00:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen to Acquire RayThera for Up to $1 Billion to Expand Immunology Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQMEk4Y0Q2RHY1SlJjUTgyVUJRSDh1elRnRTV0ZEZwMjJ2UnpIdUg2RzRxYWhfaXJRa2JrLU9UQTR0dXA2dXlwVDRqMTlJdUZ3Wk4yLTlTSnJHYjk4RU9Sb2Vqc3FabnNQZUltNTdrM0ZaNnBQeDZ0WUhOSU9BUFpnSV9wS1VzTUU1Ty1XQmdCWnVvRzk2Qk5wV2FjTzk0TkZ2Y0hFdFV6bkZDTW9mSTZxX3BR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T23:10:00+00:00", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen pays up to $1B to add RayThera immunology assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNRGpGQU1JeXppRTBmR0FqTkZhMG9kWW9ROVYxMGVWQkFmcmlXQkU5ZE1xZUlCVE9IM0pNZEhnbkREb0JMYnZxSXA2UkZSN0lFOGFoSjlrMThSNlNpcXI4UEZjS09aWXpDXzc0MEE2OWZEQXlLbl9YbUlNM0p6aWFEZDhxX1N0TUo2ME5uOEM2LWh3UEVKQmt1MHo0RFM3eXhlUjd1NExtUFJKMlhoM3AyTzU1el9PbUU1M2pB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T22:59:00+00:00", "published_display": "17 Jun 2026 22:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. stock underperforms Tuesday when compared to competitors", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNMHZfZ0ZGY2x6eUhGbE1qNVJMb0REdVFCVnZGQnFKYy1HSzJiTE1IS2dTM3FUTW5IRFhqUHpENFlJTDlaMVFDSkR5MHlMX18zWFlXOWQyWlV0d3ljTjBrV1c5dXB2TTNZa3lDazlLUXh5S09RTkhSdjBvdy1aZFBjY1dESVROS2tGZ2tVUzN0Y0taZERKbGhNUWZ2UzBVa1lIcWlsU3I1b0NaTTd0ZEdMTFdDNWVZM09CTjEwdW53SHVfS2l1VlE?oc=5", "source_name": "MarketWatch", "published_at": "2026-06-16T20:58:00+00:00", "published_display": "16 Jun 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) Stock After Breakthrough SMA And Lupus Updates Is A 9.4% Undervaluation Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T03:45:20+00:00", "published_display": "16 Jun 2026 03:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. Stock (US09062X1037): Analyst Needham Sticks With Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNSmd4dktvY3h3LXlmZjBmd3J2b3dmaGtURDYxdnNnYWJ6X2ZsUlBwSmp0RHdGTG96V0RQcHgxOWRGc2d5WE5wbUswdlhNUE9EYWdmS1AzOE02aTduQmxwd1pHQ2c4c1AwOTVMRFY5RWsyNW5UVE5odEd4RGRUb0hBZm5DSXBoYTNPdmNkb3Y4RG1QMnR3eFpiQVZkYlpoZGItc2NIeTV1UWJyUDJTTVBjRlVrQ2lqSWFxOXVoM3hFdGRibHU4MGc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-14T20:51:18+00:00", "published_display": "14 Jun 2026 20:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. stock (US09062X1037): Alzheimer\u2019s setback, pipeline hopes and what\u2019s next", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZ0hxUm5GNjk2M3hHeFYtMmVLMG10b0hJTVIxWUMtbVk3T3VEaTVGX2dqNUJ3aEZwRzAzbmR1SVA5WXhWV29XX1VwSkc5THBla2wzNDgwSXJPNEJBRURYdmpybl9CS2VUY2VfMmsxRlFyVkxuOG9EZktiejBwMlVHYmk2S1Rta2lZRnFzVkRNQktjeEw3R3R5NXBuSGhGajVnM0FWalFsVGdKUi0tbGczSDQzRGZnblBuckhaek96MEI?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-10T19:29:45+00:00", "published_display": "10 Jun 2026 19:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Stock (BIIB) Opinions on Congressional Purchases and Analyst Upgrade", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOU0NTdmVsYmd3VGZWbVR0ZGxKWkoxQlBjU1ozY0JWYWdMSHdISW4zMTNwa0h5NFNMT2FEQVprc3Q5Y1BsbTR5bU5ZT3YwNjdXYngtejZNMXFjX1IyX2plYmVvX1dzalM4Z2txUzVJT1BGUWw4eFhOemt1R182VTgwTF9Jb3I3bDdmTjV5QnJJUGlOUU5tLTRwdFR5bWZMU0xCR0ZwZEJBNlkzWi1kYVBjcmhOVkFEQQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-10T04:13:12+00:00", "published_display": "10 Jun 2026 04:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. stock (US09062X1037): Alzheimer\u2019s portfolio and pipeline in focus after recent updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQbU4za0RNZXZQSVRNODhIdG5sNlNHc2ZnTDFFcl9ZLXdUdjlnYXMtNWVXUWNUb2Y2U3RTUktpaWRsTF9jZHhBV1V6T3h5ZVlJN3dVS3h2N2t6MXpmdEV2Xy1hVm1iczh5RlJzYklycWRvV2ozSDJTajVBZUJOU2RndHBtTV9adGt6X3k2b21kLUVmdnBWUWxrNnFRZ1pNamw3WUx5WkJRZ3Zhb0Nrb3hya1NfMWMyS3Zldm56OGN6N3hoVzF2?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-08T14:54:51+00:00", "published_display": "08 Jun 2026 14:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Biogen (BIIB) Valuation After Breakthrough Therapy Status And Positive Lupus Trial Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T10:24:54+00:00", "published_display": "08 Jun 2026 10:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital raises Biogen stock price target on pipeline potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQbTZYT2ItMUZxNW53RHNjbUdYY09GWEVsR2UwRTJiU3hJaDV1RnJWUi1mVjkxcUhIajVGQjZ2bnJCV2RUVG9ySW12LS1FV0xRUFI5ZjhBNXFWYzJhcFRvUVpXYjFXaUhvd2hMWWdaQ2xXRFU4c190Yl95VWIwUnRpQTFsWlBha090cDJLWmJ2ZzdYRkw3T1FueHIxdjQwVDF0YVZXd1FrX01Fb01nbC1xejZWN2hJTGliMjgwemp1OUhQR0xk?oc=5", "source_name": "Investing.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Inc. stock (US09062X1037): Alzheimer\u2019s franchise and pipeline in focus after recent develop", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOaGU1R24xcW50aDVRa2RURklmTTNCYWNrX0ZLUnd5WHRPSmxXeldKaWM2RHQweFpKaFhWbVdpSF85WllHQkthX3p1eVRvUGpRSGhxVjJreDhuRE9ySi0zUF84YXAzd3BJeGNiMlRJZFV3R1ZacjJWSUphamNfZTkwVVNxQ0tXcnpqS1dsaFQyOVNHWjRoM1ZuVDN0ZXVaM2VDeFFKTVB1YWhLX0dXRS0tWlJnaFJmMDQ1dml4SGctRG9mTG1Y?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Wall Street Analysts Bullish on Biogen Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOU1IxbUZOOHBjX1ZEUFFQMmY2Rng0Y3RjX2FOMEFVS2RoRTBzN19Ld1FnWDJORlhfVUNHWEVZTFRsdDY1SW00QUdfU1hyQXpSX3ZWVkJmRlJYT0U5RzBIcGs4YktKWFY5eWstbnBJcFpfZ3VBMUVLWjZ4aU5lOWVHRVBXdkJYc0FOejlsSndOTTRqUS01a0g0aS1ILW84Um8wRGc?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has The Market Overlooked Biogen (BIIB) After A 62% One Year Share Price Jump", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOZUJHbk9qbTBfSlFVSFVUbEJhZ3kzc1RTZ0RXMG42bmhzOXBHaFByc0hLVk5kVVZZWGhadlJUYWVER2M4bzJ1OVRJUVlhZjBOemtFMk1kODMtR1JFNGJwYnkzUkVJS3RaSldIWW1oTHJjSnZBOWw5aHpaVmk1YnBQRnI5X01NNkkweURFTjZwWk8wRGFCQ21Pdkw1ZVg0VDJLRHpMb1dZZ0N1aWpvLUx2a3QxQTBTbjFPTGZQY2tHbDhTSkpXLVBmUDFBWEdvVVF6UVRtMHBCQdIB3AFBVV95cUxNVkZ5NzJzMjhiaVd6RVhOZ0UzSURtV21jMkxoMWVjQ2YzU2JwcEhsTWs2ekljNTF6aE85YW9uSThWSzJKYjZ3QnN2bDhMVV9JMkd5cTNsM3dmU1pBZzNkb1RrcWRuLTRaWlB2SGE4TVd6RmkwRDFxX3YzSnBvNWpzdHZWNkRCV3J5eHkwNFdMYzNPeUtwaERIMVB3RHpxOFZxN2NpT0o4dWMwek1OR0ZnWXp0SzVETDJkTzNneGZMcUQwenB1T29reVg0Zk1LRy1ycTczWmJPVDR3TWVa?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) One Off US$1.1b Loss Tests Bullish Earnings Growth Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQR2RjaUo0NFhER0dGMGZseEd3QzhvVGFpb01NcTk2c1VpcXdQMjhJM1ZUdzVCZ0g0UnFWVDZLOEpjQkNCTkhwaTVROXdXWWMya1h0Uno2ZU9Iei1RSzllOTNlaW5GUDVqU3QxRndaN3UxanA4cllFT0g3ZnB3V29DaWdxT21vUDRSUHFiX3VXelZpUy0zMFNpeXJfVVJCVENPVzVGY2NBdTBOSFFRSFlFWDlHUTBXLWJQSE1tZnhn?oc=5", "source_name": "TradingView", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biogen (BIIB) Stock Trades Up, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNek03UkJPMmJFMlJJV1VxeGMwcjRFamV2T251SEdnVGhUbXlCWldWSnBYUU0tNDdGdkxPVVhsX0RYdkpNUnZYcEtJLVk1U244aE5JMHVTMGJ0TURINWtxcEotYUkteXc4RjVoRnZwNmNRYVBodjFZZ3ZxS0hybE1XMHhMaUhyekR0RlY4SzdQQnJ1ODJUY21xVQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Biogen (BIIB) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNbGpLVEh5ck9BQzY5d1haWWlzbGRaOXliOFVxajJJY0xSVnAzQ0NjNU5WTFJmdlJUbGVYOGRSTFVyaGVfbV9WZ1N4d01ndEFwYXpBNnlHaXFuUUgyM0pta1RhRWRXeEJ0Z0NlU3pYMkVPMDEyNHA2bUxuaWFPUHJFV3dwbURUckRYQ0EwUGpBbjljdlJkcjY0RVR5cFE?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxORmRxVFJrUXVPOUF3dGZiR2IwTmJ4RDVhSUlyWWFtNC0xSWs1Rm9ocWQ0MVlCenhtMGsyMVVHOV9aNkNFMDlaMndQNXVUd05QRUJfbW9fRS1xMmtZcUNxVGJoMXZrY3VWYVFDQmI2T3NEdDExZDFIWU50Q256Rk15STlxbDVVYXBfTG1Ea2tPT0YwWnZlZTlac04wbjZGbGdEamwybnc0QTA0dTNodlpmOXpPRXRlc25aM1kzMlljZDRnZUZPczBSekVIQ2FMWlNJY0Q2anVBYk5PMzEweV9nSjBQQjR3VUNmR0dWWDVXOTItczdnUXpWaDJQajB1di11a21RMg?oc=5", "source_name": "StockStory", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: Apellis shares double on Biogen's $5.6 billion buyout plan", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNNGxkcnZoWTJSX0xRNVhTZVg3ZXF0aks5S1UtOUdPNmxQUUNod1FtcXdJMkNlZmwzSkFXbG03WURWaXVpWlhWYlowMXIyLUlhaFJxdjVvSWZoU1ZqbkZmelctTWhXVDBYZXU2U3owVUlCTThXOUhwLVYwYTRxMFVHYmFpU2tXbXRSMTRVY2RybEYyemFsek0zZWxNakpfZDI2Z0ZBVVF6VTNCWDBYRHJNMmJpamFDLTA4T25TV0xLVldkMzJBTmVqc0FHNFFSeGpIWjdmNnF0WWc1cjRrQ3haU0U5elFWSUNMVnRmZ1lfa3BjbXVQZl9QUlZ30gH_AUFVX3lxTE9xZkx4bVRGdWE5NF96b0dNTGx4bnBNSlhKWUtlVXVMSmFndDlOLV9Yd29wSXVwWllJUmxJMlo4UnM5VVp2S3FqZElkZGNWMmw0a290V05vRlVtNVUzR1lZRHU4Vm51Z2o5dElvdTlIZEJ3cHgzMHU4d1hBVFNsMVlwT3N5NFY0ZFEtZHhDZW9MQ1RMT2M0YnVlN2pIdEtubVRweUJuMktWVGFxU3F0S1NyUVFZbDdVWVZuVktZSHdvWkpNQUhaNk1NLVF4bHFIV2ZtTGNoQ1RTUl9DRm9TczhSUlIwRmZoVWdwZDlTYVVCQ3Vqbm9DVWFiQXhkeENvNA?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPbzVIbFFpSTl1Q19PNjVMZnZJWW8wTVhpcnBiN3lmWUFFVlB5X3B6SzYxYnR3R0VLWEYxRllZbXVySTdIZFgwYkswUlRWZ0piX2hYT05McjRjaEJBZERqUHM0ZDBpTEx3VDRNQVBEVjNJNG5EakxJQ3N2Mm5KZlJjdkp5akVQLTZCVTluVUFNWDdwMVBFRWU3RkJWU3F4aEpaUkFZYjRXZk03TlRqRGI2U3JWWXU3c3M?oc=5", "source_name": "TradingView", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQUE9KY3dYNktNZWVBbGM2M3F4VmUxSkxGX2RKSVM1ZUtRNjQ0UG8tUDdPSXpESVQyRU5BOW4wRXE2YmtSaTQzam9zLWI2ZUJRN3l2S1Jrd1p5dW5PaHc3NXdmb1hsQ1BBbUpqRnZmYkh1Q05KOUtrc05tMFhyRXVVTWotcnVIbVhiTGMyV2RUbjlyNU0yazBiOTZB?oc=5", "source_name": "CNBC", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has C4 Therapeutics\u2019 (CCCC) Biogen Partnership Become a Defining Test of Its Collaborative Model?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQT2F2ZGlmeUxNRlJBdGgteEI3ai1iMzNkLVVfcGtuVERqZDMxcTlVX19JY0RXOEQtZkJwaDVHRzhEak85M2F5YjluRjdOUV9UWlhQbE1KTXJRRVFHZFc5empuYmpKZVEwSG5kUXFoN09MUDdYcWc3bzNBV2FfV3FiZHgtVldqdUxtTFBSSUhBb1VkYy1CbzhUbTBGVWcxUm15anRjNnU0TnR4RVdKa0E5VlFqOFNKQTlyV0VGMEtKakdKX3F2NEQ0RkRFTFJTZ2VtOWZURlZNQ2dSWjlPRy1nVG1YTdIB6AFBVV95cUxOQ2JMVmU0ZksxS2JKVjE3VnJrMlJDdmRiYmZmOHpiRGVmUEJzQklqSEdreXdqeVd6NVkzeXpZSGRHRGgwMjNrZkhaWFRZQzZNeUs3UU43OTNNWGhZVHJjTlZ4dVpnWm9fcDNZZ2xoQ29ETTBBQlY3UVFpd0V2MHJGcXVKYkZPNkd4NHM0UVUwLUJvcDk2dlRWUHZRMEl5VjJscW5XMXJMSGRyWjF6TnpkREE0QnJCdzZUMmdpUzEyUmN2eUxma3hWQ2luOGtOdU5HSTJOdFhubk9DS1dkWXh0clhrQnpvNFEw?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-17T07:00:00+00:00", "published_display": "17 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 106, "total_relevant": 40, "sentiment_summary": {"positive": 18, "negative": 3, "neutral": 19, "score": 56, "total": 40, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 12.4, "count": 20}, {"event": "deals", "label": "Deals and strategy", "weight": 4.95, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.0, "count": 3}], "positive_events": 18, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 200.05, "latest_week": "2026-06-12", "one_week_move": 2.4, "four_week_move": 3.7, "twelve_week_move": 10.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.264459, "market_dynamics_buy_signal": false, "relative_strength": 2.405942, "fair_value_gap": 4.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 51.9364, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.4% over one week, +3.7% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 6}, {"label": "Market source", "count": 4}, {"label": "AD HOC NEWS", "count": 4}, {"label": "MarketWatch", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "GuruFocus", "count": 2}, {"label": "TradingView", "count": 2}, {"label": "The Economic Times", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Deals and strategy", "count": 9}, {"label": "Analyst action", "count": 4}, {"label": "Earnings", "count": 4}, {"label": "Regulatory and legal", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.4% over one week, +3.7% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Biogen Inc. stock outperforms competitors despite losses on the day"}], "updated_at": "2026-06-19T13:32:12.253130+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}